结构治疗学开始人类试验 新的肥胖药ACCG-2671, 目标针对食欲和脂肪损失。 Structure Therapeutics starts human trial for new obesity drug ACCG-2671, targeting appetite and fat loss.

结构治疗学已开始对ACCG-2671进行人类第一阶段试验,ACCG-2671是一个针对阿米林受体的口服小分子,目的是治疗肥胖症。 Structure Therapeutics has begun a first-in-human Phase 1 trial for ACCG-2671, an oral small molecule targeting the amylin receptor, to treat obesity. 这项研究将评估使用单剂量和多升剂量对健康个人和肥胖者的安全、可耐性和代谢效应。 The study will evaluate safety, tolerability, and metabolic effects in both healthy individuals and those with obesity using single and multiple ascending doses. 这种药物是用基于结构的方法设计的,目的是模仿阿米林在减少食欲和增加讽刺性方面的作用。 The drug, designed via structure-based methods, aims to mimic amylin’s role in reducing appetite and increasing satiety. 它属于一种双亚米林和卡西托宁受体激动剂的类别,可以减少脂肪质量,同时保留瘦组织。 It belongs to a class of dual amylin and calcitonin receptor agonists, which may reduce fat mass while preserving lean tissue. 该公司还在临床前期和临床阶段开发其他候选人,包括与GLP-1受体激动剂的潜在组合。 The company is also developing other candidates in preclinical and clinical stages, including potential combinations with GLP-1 receptor agonists.